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Catheter ablation of atrial fibrillation (AF) is nowan important therapeuticmodality for patientswithAF. There is considerable evidence available
fromseveral prospective randomized trials demonstrating that catheter ablationofAF is superior to antiarrhythmicdrug therapy in controllingAF
and that AF ablation improves quality of life substantially. This is especially true for patients with paroxysmal AFwithout other severe comorbid-
ities. Catheter ablation is indicated for treatment of patients with symptomatic AF in whom one or more attempts at class 1 or 3 antiarrhythmic
drug therapy have failed. Although current guidelines state that is appropriate to perform catheter ablation as a first-line therapy in selected
patients, in our clinical practice this is rare. This reflects a number of important realities concerning the field of AF ablation. Catheter ablation
of AF is a challenging and complex procedure, which is not free of the risk of potentially life-threatening complications, such as an atrio-
oesophageal fistula, stroke, and cardiac tamponade. Although thesemajor complications are rare and their rate is falling, theymust be considered
by both patients and physicians. The progressmade and the newdevelopments on the horizon in the field of AF catheter ablation are remarkable.
When radiofrequency catheter ablation was first introduced in the late 1980s, few would have predicted that catheter ablation of AF would
emerge as the most commonly performed ablation procedure in most major hospitals.
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Introduction
Atrial fibrillation (AF) is themost commonsustained tachyarrhythmia
encountered in clinical practice and affects1%of the general popu-
lation with increased incidences in the elderly population. Currently
5 million people are affected in Europe.1 About 6% of the popu-
lation group aged 60 years or more has AF. Atrial fibrillation has
an important impact on morbidity and mortality in these patients.
Pharmacological therapy to suppress arrhythmia is frequently un-
successful due to low efficacy and/or side effects. Catheter ablation
of AF has advanced since 15 years to a well established and widely
performed interventional therapy for many patients with symptom-
aticAF.2–4 Several prospective randomized trials have demonstrated
the superiority of catheter ablation over antiarrhythmic drug therapy
in patients with paroxysmal AF and structurally normal hearts.
Current techniques of atrial
fibrillation ablation
More than 15 years ago, the basis for the development of catheter
ablation of AF was established when foci of ectopic beats originating
from the pulmonary veins were observed to be capable to trigger
AF.5,6 Sincethem, circumferential ablation around the orifices of
the pulmonary veins with the procedural endpoint of electrical
deconnection of the pulmonary vein from the left atrium has
become the cornerstone of catheter ablation of AF. The ablation
consists of a series of point-by-point radiofrequency lesions encirc-
ling each or both ipsilateral ostia of the pulmonary veins (Figure 1).
Most centres perform this ablation lesions set using a transvenous
irrigated radiofrequency ablation catheter inserted through the
femoral vein.7–9 Cryoenergy or laser light is used as alternatives to
conventional radiofrequency energy applied through balloon-tipped
catheters (Figure 2). The anatomical variation of the pulmonary
vein ostia presents important hurdles for the one-size-fits-all
balloon-based catheters. High-intensity focused ultrasound energy
was removed from the market because of high incidence of a left
atrio-oesophageal fistula.
Pulmonary vein isolation is confirmed by a circular multipolar
mapping catheter placed into the pulmonary vein showing entrance
block (Figures 3 and 4). In addition, pulmonary vein isolation can be
proved by pacing inside the pulmonary vein and documentation
of an exit block out of the pulmonary vein.10 Residual gaps in the ab-
lation line can be rapidly identified by pacing from the tip of the
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mapping catheter and ablating to obtain conduction block and
isolation of the pulmonary veins, proposed as the pace-and-ablate
approach.11
The procedure is carried out with fluoroscopy and a three-
dimensional electroanatomical mapping system, which also allows
the integrationofpre-acquiredMRIorCT images.Theablation isper-
formed either with deep conscious sedation or with general anaes-
thesia depending on patient’s condition and centre’s preference.
Patients who present in AF and have not been continuously anticoa-
gulated with warfarin undergo a transoesophageal echocardiogram
to rule out thrombus formation in the left atrium prior to ablation.
The presence of a left atrial thrombus precludes a left atrial ablation
procedure. Patients are commonly admitted on a short-stay basis.12
Atrial fibrillation ablation procedures are routinely performed
on anticoagulated patients with warfarin or phenprocoumon who
have a therapeutic INR. Novel oral anticoagulation agents, such as
thrombin inhibitors (dabigatran)or factorXa inhibitors (rivaroxaban,
apixaban), are now increasingly used in the pre- and post-procedural
anticoagulation regimen of patients undergoing AF ablation.13 Fast
onset of action and pharmacodynamic elimination make these
novel oral anticoagulants especially attractive in this patients group.
Conversely, an important limitation of these new anticoagulant
agents is the absence of a reversal agent. Because of this, most
centres will hold these novel anticoagulants for 1 to 2 days prior
to an AF ablation procedure and resume them 3–4 h after the
procedure is completed.
Success rates of atrial fibrillation
ablation
Success rates of catheter ablation of AF depend mainly on three
variables: the patient, the electrophysiologist, and the definition of
success. The type of AF (paroxysmal, persistent, or long-standing
persistent AF), concomitant structural heart disease, comorbidities
such as obesity and sleep apnoea determine the success rates.
Furthermore, high-success rates and low-complication rates are
achieved in high-volume and experienced centres. Results from
various centres differ greatly because of divergent ablation techni-
ques, reporting and follow-up protocols. Standardization of practice
is required to obtain consistent and comparable outcome data in this
field. The HRS/ EHRA/ ECAS (Heart Rhythm Society/European
Heart Rhythm Association/European Cardiac Arrhythmia Society)
Consensus Document on AF ablation recommends that success
should be defined as freedom from symptomatic or asymptomatic
AF, atrial tachycardia, or atrial flutter lasting ≥30 s at a 12-month
follow-up after AF ablation.2 It is recognized that this definition
of success is very strict and best used for clinical trials. A 3-month-
blanking period after AF ablation, in which recurrences of atrial
arrhythmia are not considered as failure of the procedure, is recom-
mended because a majority of patients develops temporary AF or
atrial flutter shortly after the ablation procedure, in part due to tran-
sientmyo- andpericardial inflammation. Fromaclinical perspective, a
marked reduction of symptomatic AF is considered as a successful
result from a patient’s and a physician’s perspective.
Two recent meta-analyses involving 63 AF ablation studies
reported that the single-procedure success of ablation with no anti-
arrhythmic drug therapy was 57%, the multiple-procedure success
rate with no antiarrhythmic drug therapy was 71%, and the multiple-
procedure success rate with antiarrhythmic drugs was 77%. In com-
parison, the success rate for antiarrhythmic drug therapy was 52%.14
There have been at least 12 prospective, randomized clinical trials
comparing the results of AF ablation with antiarrhythmic drug
therapy.15–22 A meta-analysis of four of these studies reported that
76% of patients treated with catheter ablation were free of AF com-
pared with 19% of patients randomized to antiarrhythmic drugs.23
The authors concluded that there was a .3.7-fold probability of
remaining in sinus rhythm with catheter ablation than with antiar-
rhythmic drug therapy. MANTRA-PAF (Medical ANtiarrhythmic
Treatment or Radiofrequency Ablation in Paroxysmal Atrial Fibrilla-
tion) compared first-line catheter ablation of AF to antiarrhythmic
drugs in 294 patients. At 2 years, significantly more patients in the
Figure 1 Three-dimensional electroanatomical map of the left
atrium and the pulmonary vein ostia in a posterior projection
with circumferential ablation lesions (red points) around ipsilateral
pulmonary veins.
Figure2 The laser balloon ablation catheter consistsof a variable
diameter and compliant balloon, and an atraumatic and flexible tip.
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ablation group were free from any AF (85 vs. 71%) and symptomatic
AF (93 vs. 84%).21 Quality of life was significantly better in the cath-
eter ablation arm. In RAAFT-2 (Radiofrequency Ablation vs. Antiar-
rhythmic Drugs as First-Line Treatment of Paroxysmal Atrial
Fibrillation), the recurrence rate of AF was significant lower after ab-
lation compared with antiarrhythmic drugs after 2 years among 127
patients with paroxysmal AF without previous antiarrhythmic drug
treatment. Quality of life improved in both treatment groups.22
Similar results were found if cryoenergy was used for ablation of
AF for treatment-naive patients in STOP AF (Cryoballoon ablation
of pulmonary veins for paroxysmal atrial fibrillation: first results of
the North American Arctic Front pivotal trial).19
There is only little evidence from prospective, randomized, multi-
centre clinical trials in patients with chronic AF, both persistent (.1
week) and long-standing persistent (.12months of continuous AF).
However, the recently published prospective randomized TTOP-AF
trial (Tailored Treatment of Persistent Atrial Fibrillation) in patients
with persistent and long-standing persistent AF demonstrated a sig-
nificant greater reduction of AF at 6 months after ablation compared
with medical treatment (56 vs. 26%).24 While the primary goal of
most electrophysiologists performing an ablation in patients with
paroxysmalAFwill be the pulmonary vein isolation using a circumfer-
ential ablation approach, the strategies used for ablation of patients
Figure3 Therecordings fromthecircularmultipolarmappingcatheterplaced inapulmonaryveinareshownduringablation (Lasso1–22 Lasso19–20).
On Lasso1–2 prolongation of conduction delay from the atrium into the pulmonary vein is seen on the first four beats before the sharp local pulmonary
vein potential finally disappears on beat 5 and 6 as a result of successful pulmonary vein isolation. CS, coronary sinus; Abld, distal ablation catheter.
Figure4 Image integration technology combines the electroana-
tomical reconstruction of the left atrium (green) and the fluoros-
copy image into a single overlapping image aiming to reduce
radiation exposure for both the patient and the operator. The
circular multipolar mapping catheter is placed in the right upper
pulmonary vein which is filled with a contrast dye.
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with non-paroxysmal AF are far more varied and less well supported
by evidence.2,25–28 Currently, there is a lack of evidence and a large
debate among electrophysiologists as to what is the optimal ablation
strategy in patients with non-paroxysmal AF.27,28 A meta-analysis
of studies reporting the results of catheter ablation of persistent
and long-standing persistent (.12 months of continuous AF) con-
cluded that the success rate of different strategies is similar, provided
that pulmonary vein isolation was performed.29
The role of the left atrium as a substrate in the progression of
paroxysmal to chronic AF is still not fully understood. Some patients
having the same characteristics stay in paroxysmal AF for years, while
others develop persistent AF within few months after the first
episode of AF. Therefore, the phenotypical classification into parox-
ysmal vs. persistentAF is frequently not directly related to the degree
of atrial fibrosis in this heterogeneous patient group.
Based on the review of the literature and in our experience, we
would estimate the single-procedure efficacy of AF ablation in an
optimal candidate for AF ablation with paroxysmal AF to be
between 60 and 80%. The efficacy of a single procedure in a less
optimal patient, such as a patient with persistent AF, lies between
50 and 70%.
A large number of studies concerning the long-term efficacy of AF
ablation have been published.30–32 In a series of 264 patients, late
recurrence after 5 years was reported more likely in patients with
hypertension and hyperlipidaemia.30 A recent large study reported
long-term freedom from AF in 47% of patients after 4.8 years of
follow-up.31 If a patient is brought back to the electrophysiology
laboratory with recurrent AF, recurrence of pulmonary vein con-
duction is almost universally observed. This finding highlights the
difficulty in performing permanent pulmonary vein isolation with
current ablation techniques. Furthermore, iatrogenic organized left
atrial tachycardias after AF ablation are reported with an incidence
of 1.2–40%. The frequency of occurrence appears to depend on the
typeof ablation strategyand theextent of underlying atrial disease. Ab-
lation strategies combining pulmonary vein isolationwithextensive left
ablation using linear lesions and targeting complex fractionated atrial
electrograms (CFAEs) will facilitate the occurrence of the secondary
atrial tachycardia mechanisms due to slow conduction induced by
incomplete linear lesions.Thesearrhythmias are frequently verysymp-
tomatic because of rapid ventricular rate responsewith commonly 2:1
AV conduction. They respond poorly to drug therapy and require
further ablation procedures.
There is a lotof evidence that ablation is superior to antiarrhythmic
drugs, especially in patients with paroxysmal AF and structurally
normal hearts, which is reflected in current guidelines and accepted
in clinical practice.
Complications of atrial fibrillation
ablation
Catheter ablation of AF is a challenging and complex invasive proced-
ure,which isassociatedwithariskofmajorcomplications.An internation-
al survey in 2005 reported a 6% incidence of major complications
(tamponade, stroke, pulmonary vein stenosis, or death).33 A recent
update of this survey reported a 4.5% complication rate.34 Another
report from an international survey of AF ablation of 162 centres
provided details on 32 deaths that occurred during or after AF
ablation procedures in 32 569 patients (0.1%).35 Death was due to
tamponade in eight patients (25% of deaths), to stroke in five
(16%), to atrio-oesophageal fistula in five (16%), and pneumonia in
two (6%). There ismore recent data suggesting that the complication
rate of AF ablation is decreasing.36,37 A recent consecutive series
of patients undergoing AF ablation reported a major complication
rate of 0.8%, with no instances of death, stroke, atrio-oesophageal
fistula, or pulmonary vein stenosis.36
Oesophageal injury due to tissue heating at the posterior wall of
the left atrium ranges from frequent mild ulceration to very rare
fatal left atrio-oesophageal fistula. Limitation of power applied to
the posterior left atrial wall, especially while ablating close to the
oesophagus, visualized by a contrast-mediafilled gastric-oesophageal
tubeorby image integrationofCTorMRI, aswell as luminal tempera-
ture monitoring to identify potentially dangerous heating of the
oesophagus during ablation and the treatment with proton pump
inhibitors may prevent a left atrio-oesophageal fistula. However,
there are no evidence-based data available demonstrating that
these measures reduce the incidence of this very rare complication
which is estimated ,0.1%.38
On the basis of our review, as well as our clinical experience, we
would estimate that the current incidence of major complications
lies between 1 and 5%. The incidence is 0.5–2% for tamponade,
0.3–1%for stroke,0.5–2% forvascular injury, and,1% forpulmonary
vein stenosis, and the risk for development of an atrio-oesophageal
fistula and/or death is,0.1%. Further developments of the technique
are required to improve the safety of an AF ablation procedure.
Unanswered questions concerning
the outcome of atrial fibrillation
ablation
Several prospective randomized trials have demonstrated that cath-
eter ablation is superior to antiarrhythmic drug therapy in patients
with paroxysmal AF and structurally normal hearts. However,
there are many important unanswered questions. More information
is needed on the impact of AF ablation on mortality and stroke risk
beyond rhythm and symptom control. Although patients with AF
have an increased risk of stroke and increased mortality, it is
unclear whether AF ablation reduces the risk of stroke and improves
survival. There are some large case series that have reported a low
risk of stroke after AF ablation.39 Although the stroke rate is low in
these series, few patients at high risk of stroke were monitored
after anticoagulation was stopped for a significant period of time. It
is for this reason that the HRS Consensus Document concluded
that a desire to discontinue anticoagulation therapy is not an appro-
priate indication for AF ablation and that the patient’s CHA2DS2-
VASc score [congestive heart failure, hypertension, age ≥75
(doubled), diabetes, stroke (doubled), vascular disease, age 65–75,
and sex category (female)], rather than the presence or absence of
AF, should be used to determine the appropriate anticoagulation
approach after an AF ablation procedure.2
The impact of AF ablation on both stroke and survival is currently
being evaluated in the CABANA trial (Catheter Ablation vs.
Antiarrhythmic Drug Therapy for Atrial Fibrillation) and the EAST
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study (Early Treatment of Atrial Fibrillation for Stroke Prevention
Trial).40–42
Most AF ablation trials enrolled white male patients ,70 years of
age.43–45 It, therefore, remains uncertain what the safety and efficacy
ofAF ablation are in elderly patients.Nodifference in the success and
complication rates was observed in a study comparing the outcome
of three subsets of patients (patients ,65 years of age, patients
between the ages 65 and 74 years, and patients older than 75
years).30 However, patients .75 years old were less likely to
undergo repeated procedures and preferred to continue antiar-
rhythmic drug therapy.
A number of clinical trials have addressed the role of catheter ab-
lation of AF in patients with heart failure. The first study addressing
this topic examined the impact of AF ablation in 58 patients with
heart failure with an ejection fraction ,45% and in 58 control sub-
jects. During a follow-up of 1 year, 78% of patients with heart
failure and 84% of control subjects remained in sinus rhythm.
Of particular note is that the ejection fraction improved by 21+
13%. Improvements were also seen in exercise capacity and quality
of life. Another study, the PABA-CHF study (Pulmonary Vein
Antrum Isolation vs. AV Node Ablation with Bi-Ventricular Pacing
for Treatment of Atrial Fibrillation in Patients with Congestive
Heart Failure) compared the outcome of AF ablation with the abla-
tion of the atrioventricular node after pacemaker implantation.46
The trial showed anoverall superiorityof pulmonary vein antrum iso-
lation to atrioventricular node ablation, as evidencedbyan increase in
quality of life, longer walking distance (340 vs. 297 m), and a higher
ejection fraction (35 vs. 28%). Only few data are available on cost-
effectiveness of AF ablation. A successful catheter ablation of AF
would potentially significantly reduce healthcare resource utilization,
especially if large randomized prospective trialswill demonstrate that
successful AF ablation reduces the risk of stroke. A decision analytic
model using data from a randomized study comparing first-line
catheter ablation to antiarrhythmic drug therapy showed that the
costs of ablation were neutralized in patients with paroxysmal symp-
tomatic AF 2 years after an initial procedure compared with drug
therapy.47
Guidelines for the catheter
ablation of atrial fibrillation
The Consensus Statement on catheter and surgical ablation of atrial
fibrillation of the HRS/ EHRA/ECAS and the Guidelines for the man-
agement of patients with atrial fibrillation of the ESC (European
Society of Cardiology), the AHA (American Heart Association),
the ACC (American College of Cardiology), and the HRS recom-
mend the catheter ablation of symptomatic paroxysmal AF after
failure of at least one class 1 or 3 antiarrhythmic agent.2–4 This indi-
cation is stratified as class I and levelA.Catheter ablation as a first-line
therapy is considered as reasonable (class IIa, level B indication) in
selected patients with paroxysmal AF without structural heart
disease. The same level of indication accounts for patients with per-
sistent AF after failed antiarrhythmic drug therapy. Currently, the
primary goal of catheter ablation of AF is control of symptoms and
improvement of quality of life.40–42
New techniques and future
perspectives
Ongoing developments of new ablation tools will improve safety and
efficacyofAFablation. Theywill shorten procedure time and learning
curve allowing the procedure to be performed by less skilled opera-
tors, resulting in an opening of this therapeutical modality to a higher
proportion of patients with AF.
An alternative to radiofrequency energy for lesion creation is
cryoenergy, which is available in a cryoballoon ablation system for
the clinical use for treatment of patients with paroxysmal AF. This
balloon-based ablation system isolates each pulmonary vein by freez-
ing the tissue below2808C.19 It appears that cryoballoon ablation is
best suited for patientswith paroxysmal AFwith comparable efficacy
and safety to conventional ablation with radiofrequency.
Another alternative energy is laser light which is also applied
through a balloon-based ablation system that enables direct visualiza-
tion of the pulmonary vein ostium (Figure 2). In 200 patients electrical
isolation was achieved in 99% of the targeted pulmonary veins. At 12
months, 60%of patientswere in sinus rhythmwithout antiarrhythmic
drugs.48
A recent studyshowed that remainingpulmonary vein activity after
ablation was an independent predictor of AF recurrence and recom-
mend additional ablation for spontaneous dissociated pulmonary
vein activity after pulmonary vein isolation.49
Another novel approach, referred to as pulmonary antrum radial-
linear ablation, consists of creating six to eight short ablation lines
starting from the pulmonary vein ostium. The endpoint was not elec-
trical isolation, but completion of the ablation lines, conversion into
sinus rhythm and non-inducibility of AF.50 At 14 months, 74% of
patients treated with pulmonary antrum radial-linear ablation were
free from AF compared with 50% of patients treated by pulmonary
vein isolation.
Contact force determines the size of ablation lesions. Novel
ablation catheters have been developed that provide instantaneous
feedback on the degree and orientation of force with which the
ablation catheter is contacting the atrial wall (Figure 5).51 Initial ex-
periences are encouraging; however, definitive outcome data are
not yet available.
Other ablation strategies than aiming pulmonary vein isolation are
being developed, such as ablation of CFAEs. In a single-centre study,
81% of 674 patients were in sinus rhythm at 5 year after ablation of
CFAEs. 26,52 However, other groups could not replicate these
impressive results likely due to the subjective nature of defining
CFAEs by visual inspection.
One-third of patients develop a vagal reflex during AF ablation and
this group have a 99% success rate as compared with a 85% success
rate among patients without vagal reflex during ablation.53 However,
the findings are somewhat controversial and the role of ablation of
autonomic ganglia remains to be better defined.
Another recent and novel approach consists ofmapping and ablat-
ing localized areas other than pulmonary veins, referred to as elec-
trical rotors.54 Contact mapping using a 64-polar basket catheter
and computational mapping identify localized sources for AF. At a
follow-up of 273 days and after a single-procedure, patients treated
with an additional ablation of localized electrical rotors were
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significantly more frequently free from AF (82%) compared with
patients treated by pulmonary vein isolation alone (45%).
There are two ablation tools available that allow remote and
robotic ablation. The first is a robotic magnetic navigation system
that consists of two permanent magnets placed on either side of
the patient, and the second is a remote navigation system that uses
a robotically steerable sheath.55,56 As of today, the goals of improved
efficacy and safety and shortening of procedure times have not been
metyet and fewelectrophysiologistsworldwide relyon these robotic
systems.
Recently, a numberof studies havedemonstrated thevalueofusing
magnetic resonance imaging (MR) to image myocardial scar, both
before ablation as a predictor of success and after ablation.57 More-
over, substantial progress has been made on developing the tools to
allow electrophysiology studies and catheter ablation procedures to
be performed in aMR scanner.58 Magnetic resonance imaging is radi-
ation free, allows imaging of myocardial tissue and structures and ab-
lation lesions, and is similar in cost to a biplane fluoroscopy system.
Despite these theoretical advantages, the obstacles to performing
catheter ablation in an MR environment are considerable. Research
on developing MR-based ablation is ongoing.
Conclusions
Catheter ablationof AF is nowan important therapeuticmodality for
patients with AF. There is considerable evidence available from
several prospective randomized trials demonstrating that catheter
ablation of AF is superior to antiarrhythmic drug therapy in control-
ling AF and that AF ablation improves quality of life substantially. This
is especially true for patients with paroxysmal AF without other
severe comorbidities. Catheter ablation is indicated for treatment
of patients with symptomatic AF in whom one or more attempts at
class 1 or 3 antiarrhythmic drug therapy have failed. Although
current guidelines state that is appropriate to perform catheter abla-
tion as a first-line therapy in selected patients, in our clinical practice
this is rare. This reflects a number of important realities concerning
the field of AF ablation. Catheter ablation of AF is a challenging and
complex procedure, which is not free of the risk of potentially life-
threatening complications, such as an atrio-oesophageal fistula,
stroke, and cardiac tamponade. Although these major complications
are rare and their rate is falling, they must be considered by both
patients and physicians. The progress made and the new develop-
ments on the horizon in the field of AF catheter ablation are remark-
able. When radiofrequency catheter ablation was first introduced in
the late 1980s, fewwould have predicted that catheter ablation of AF
would emerge as themost commonly performed ablation procedure
in most major hospitals.
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